2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of non-research payments from Open Payments Database between 2014 and 2020

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          To evaluate the trend in non-research payments made by the industries to the infectious disease physicians in the United States since the launch of the Open Payments Database and during the COVID-19 pandemic.

          Methods

          Descriptive analysis was performed for the non-research payments made to all infectious disease physicians listed in the Open Payments Database between 2014 and 2020. Using the generalized estimating equation models with panel-data of monthly and yearly payment per physician, the payment trend since the inception of the Open Payments Database and during the early stage of the COVID-19 pandemic were evaluated.

          Results

          A total of 7901 (81.5%) infectious disease physicians received $156,837,987 in non-research payments between 2014 and 2020. Median annual payments were $197‒$220. Monthly non-research per-physician payments and number of physicians with payments rapidly decreased by 58.6% (95% confidence interval [95% CI]: 49.7%‒65.9%, p<0.001) and by 54.4% (95% CI: 52.7%‒56.1%, p<0.001) at the beginning of the COVID-19 pandemic, respectively. However, the per-physician payments and number of physicians with payments slightly increased every month right after onset of the pandemic. Both per-physician payments and the number of physicians with payments decreased by 2.6 (95% CI: 0.45%‒4.7%, p=0.018) and 2.0 (95% CI: 1.6‒2.4, p<0.001) since the inception of the Open Payments, respectively.

          Conclusions

          The non-research payments and number of infectious disease physicians accepting payments had decreased since the inception of the Open Payments Database. Furthermore, the non-research payments to infectious disease physicians suddenly decreased by more than half due to the COVID-19 pandemic.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?: A Systematic Review

          Financial payments from the drug industry to U.S. physicians are common. Payments may influence physicians' clinical decision making and drug prescribing.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.

            Pharmaceutical industry payments to physicians may affect prescribing practices and increase costs if more expensive medications are prescribed.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Trends in Industry Payments to Physicians in the United States From 2014 to 2018

                Bookmark

                Author and article information

                Journal
                Clin Microbiol Infect
                Clin Microbiol Infect
                Clinical Microbiology and Infection
                European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
                1198-743X
                1469-0691
                5 August 2022
                5 August 2022
                Affiliations
                [1 ]Medical Governance Research Institute, Minato-ku, Tokyo, Japan
                [2 ]Tohoku University School of Medicine, Sendai City, Miyagi, Japan
                [3 ]Hamamatsu University School of Medicine, Hamamatsu City, Shizuoka, Japan
                [4 ]School of Engineering, Hokkaido University, Sapporo City, Hokkaido, Japan
                [5 ]Department of Internal Medicine, Soma Central Hospital, Soma City, Fukushima, Japan
                [6 ]Department of Internal Medicine, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
                [7 ]Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City, Fukushima, Japan
                Author notes
                []Corresponding author: Anju Murayama Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan Tel.: +81 90-6321-6996
                Article
                S1198-743X(22)00391-3
                10.1016/j.cmi.2022.07.023
                9352402
                3de8880e-a138-438c-bf35-47208c10cd54
                © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 24 April 2022
                : 17 July 2022
                : 23 July 2022
                Categories
                Research Note

                Microbiology & Virology
                covid-19,health policy,industry payments,infectious disease physician,open payments,physician payment,physician payments sunshine act,sars-cov-2,united states

                Comments

                Comment on this article